黄芪注射液配合化疗对晚期非小细胞肺癌患者生存质量的影响

目的 :观察黄芪注射液配合化疗对晚期非小细胞肺癌 (non smallcelllungcancer ,NSCLC)患者生存质量的影响。方法 :6 0例晚期NSCLC患者随机分为黄芪注射液加化疗组 (治疗组 ) 30例和单纯化疗组(对照组 ) 30例 ,两组化疗均采用MVP方案 ,治疗组同时辅以黄芪注射液 6 0ml/天静脉滴注 ,2 1～ 2 8天为 1个周期 ,治疗 2～ 3个周期。结果 :治疗组有效率为 4 0 0 % ,对照组为 36 7% ;治疗、对照组平均缓解期、中位生存期及 1年生存率分别为 5 4个月和 3 3个月 ,11个月和 7个月 ,4 6 7%和 30 0 % ,差异均有显著性 (P <0 0 5 ) ;患者的临床症状总改善率 ,生存质量提高阳性率 ,治疗组为 80 4 % ,4 3 3% ,与对照组 (5 0 0 % ,2 3 3% )比较 ,差异有显著性 (P <0 0 1)。结论 :黄芪注射液配合化疗可显著改善晚期NSCLC患者的生存质量。

英文摘要:

Objective: To observe the effect of Astragalus injection (AI) combined with chemotherapy on quality of life (QOF) in patients with advanced non-small cell lung caner (NSCLC). Methods: Sixty NSCLC patients were randomly divided into the treated group (n=30,treated with AI combined with chemotherapy) and the control group (n=30, treated with chemotherapy alone). Chemotherapy of MVP protocol was applied to both groups. AI was supplemented to the treated group by intravenous dripping 60 ml per day. Treatment of 21-28 days as one treatment cycle, and 2-3 treatment cycles were applied. Results: The effective rate in the treated group was 40.0% and in the control group was 36.7%, the mean remission rate in the treated and control group was 5.4 months and 3.3 months, the median survival period 11 months and 7 months, and the 1-year survival rate 46.75% and 30.0%, respectively, the differences of these indexes between the two groups were all significant (P<0.05). Moreover, the clinical improving rate and QOF elevation rate in the treated group was 80.4% and 43.3%, as compared with those in the control group (50.0% and 23.3% respectively), the difference was also significant (P<0.01). Conclusion: AI combined with chemotherapy can significantly improve the QOF in NSCLC patients of advanced stage.

关闭